Mylan Launches Generic Faslodex Injection for the Expansion of its Oncology Portfolio in the US

 Mylan Launches Generic Faslodex Injection for the Expansion of its Oncology Portfolio in the US

Mylan Launches Generic Faslodex Injection for the Expansion of its Oncology Portfolio in the US

Shots:

  • Mylan launches Fulvestrant Injection (50 mg/mL)/single-dose prefilled syringe which is a generic version of AstraZeneca’s Faslodex Injection and has received FDA’s ANDA as monothx. for advanced BC in women with menopause and combination therapy for advance & m-BC
  • The launch of Fulvestrant Injection expands Mylan’s oncology portfolio and available treatment options for women facing advanced/m-BC
  • Fulvestrant Injection is a prescription therapy used to treat multiple forms of advanced breast cancer and has generated ~$550M in 12mos. ending Jun 30, 2019

Click here to­ read full press release/ article | Ref: Mylan | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post